LPL and nephrotic syndrome: However, one of its most studied roles is as a regulator of lipid metabolism, having been shown to modulate both intracellular and extracellular lipolysis [206], and linked to lipoprotein lipase inhibition and hypertriglyceridemia in nephrotic syndrome [173,202,204,206,207,208], which correlates well with the increased serum triglyceride levels (Figure 3) and decreased liver Lpl expression (Figure 6a) observed in tapentadol groups.